Rapid Clinical Improvement With Tyrosine Kinase 2 Inhibitor Deucravacitinib in Overlapping Psoriasis and Atopic Dermatitis
- PMID: 40237138
- DOI: 10.1111/ijd.17742
Rapid Clinical Improvement With Tyrosine Kinase 2 Inhibitor Deucravacitinib in Overlapping Psoriasis and Atopic Dermatitis
Keywords: atopic dermatitis; inflammatory diseases; psoriasis treatment.
References
-
- A. Caro‐Chang and M. Fung, “Eosinophils in Psoriasis: A Systematic Review and Meta‐Analysis Introducing a Study Quality Assessment Tool for Diagnostic Pathology Studies,” Journal of Cutaneous Pathology 51, no. 6 (2024): 441–449, https://doi.org/10.1111/cup.14604.
-
- C. Carlos, F. Tous‐Romero, C. García‐Donoso, et al., “Upadacitinib for the Management of Overlapping Psoriasis and Atopic Dermatitis: A Case Series,” International Journal of Dermatology 64, no. 3 (2025): 623–625, https://doi.org/10.1111/ijd.17512.
-
- K. Yatsuzuka, J. Muto, N. Kohri, S. Yoshida, K. Shiraishi, and Y. Fujisawa, “The Use of Upadacitinib to Successfully Treat Eczematized Psoriasis,” International Journal of Dermatology 64, no. 3 (2025): 582–583, https://doi.org/10.1111/ijd.17528.
-
- M. Dragotto, M. D'Onghia, E. Trovato, L. Tognetti, P. Rubegni, and L. Calabrese, “Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition,” Journal of Clinical Medicine 13, no. 11 (2024): 3091, https://doi.org/10.3390/jcm13113091.
-
- L. Felix and E. Kilian, “Eczematized Psoriasis ‐ a Frequent but Often Neglected Variant of Plaque Psoriasis,” JDDG: Journal der Deutschen Dermatologischen Gesellschaft 21, no. 5 (2023): 445–453, https://doi.org/10.1111/ddg.14991.
Grants and funding
LinkOut - more resources
Full Text Sources